Exponent, Inc. — Form 10-Q Summary
Period: The filing covers the quarter and nine months ended October 2, 2015, compared with periods ended October 3, 2014. The request metadata says “2014 Q3,” which conflicts with the filing’s stated 2015 reporting period.
Business context and results
Exponent is an engineering and scientific consulting firm operating through Engineering and Other Scientific and Environmental and Health segments. Amounts below are in U.S. dollars; financial statement amounts are in millions unless noted.
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $79.0 | $78.6 | $239.2 | $231.1 |
| Revenue before reimbursements | $74.5 | $74.3 | $225.9 | $219.6 |
| Operating income | $20.9 | $19.2 | $54.7 | $49.4 |
| Net income | $11.7 | $11.0 | $33.7 | $31.5 |
| Diluted EPS | $0.43 | $0.40 | $1.23 | $1.13 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $34.3 | $26.1 |
Financial position, cash flow and capital returns
- At October 2, 2015, cash and cash equivalents were $124.5 million and short-term investments were $26.8 million, totaling $151.3 million. Total assets were $369.0 million; current assets were $269.5 million and current liabilities $69.6 million.
- Total liabilities were $112.2 million. The balance sheet reports no interest-bearing debt; the filing does not provide a separate debt schedule. Management said existing cash and investments should meet working capital, capital expenditure, repurchase, dividend and other needs for at least the next 12 months.
- Nine-month investing cash outflow was $6.8 million, including $4.4 million in capital expenditures and net purchases of short-term investments. Financing cash outflow was $32.4 million, including $19.8 million of repurchases and $11.8 million of dividends and dividend equivalents. Cash decreased $5.0 million from year-end 2014.
- Quarterly dividend was $0.15 per share, up from $0.125 a year earlier. The board declared another $0.15 dividend payable December 18, 2015, subject to the stated record date.
- Nine-month EBITDA was $59.1 million, or 26.1% of revenue before reimbursements, compared with $56.0 million and 25.5% in 2014. These are company-defined non-GAAP measures.
Changes and operating trends
- Q3 revenue increased 0.6%; nine-month revenue rose 3.5%. Operating income increased 8.7% in Q3 and 10.6% for the nine-month period; net income rose 6.2% and 7.3%, respectively.
- Engineering and Other Scientific revenue grew 6.2% in Q3 and 6.9% year to date. Environmental and Health revenue declined 14.8% in Q3 and 5.7% year to date. A major investigation ended in July 2015, and weaker health-center demand contributed to the declines.
- Management cited demand in several engineering practices, including materials and corrosion, biomedical, polymer science and vehicle analysis. Technology development activity continued to step down, attributed to defense-spending constraints and troop withdrawals from Afghanistan.
- Q3 billable hours were nearly flat at 286,000 versus 285,000; utilization fell to 73% from 74%. Nine-month billable hours increased in Engineering and Other Scientific but declined in Environmental and Health.
- Q3 operating margin was approximately 26.5% of total revenue (20.9/79.0), versus 24.5% a year earlier. The quarter included a net $2.1 million other expense, mainly reflecting deferred-compensation investment value changes; these changes also affect compensation expense. Nine-month other income declined to $0.5 million from $2.7 million.
Outlook, risks and unusual items
- No quantified revenue or earnings guidance is provided. Management expects the investigation-related work to be de minimis and anticipates continued reduced technology-development activity. It expects compensation, other operating and general and administrative costs to increase as it hires selectively and invests in infrastructure, business development and staff development.
- Management described liquidity as sufficient for at least 12 months and said cash may support repurchases, dividends, capital expenditures or complementary acquisitions. On October 21, 2015, the board authorized an additional $35 million of repurchases, bringing authorization to approximately $50 million.
- Risks cited include demand and economic conditions, engagement timing, competition and pricing, lack of backlog, hiring and retention, regulation and tort reform, and claims. The company also faces foreign-currency and interest-rate exposure; it does not use foreign-exchange contracts. Management said a 10% currency move on specified non-functional-currency net assets could produce an approximately $0.21 million gain or loss.
- The company reported no material legal proceedings and no material changes to previously disclosed risk factors. It said legal matters in the ordinary course were not expected to materially affect financial condition, results or liquidity, while noting outcomes remain uncertain.
Key facts for investors to verify
- Confirm the intended period: the supplied metadata says 2014 Q3, but the filing is for Q3 2015.
- Assess whether weakness in Environmental and Health and technology development persists, including the effects of the ended investigation and health-center demand.
- Separate underlying operating trends from deferred-compensation market-value effects and review the company-defined non-GAAP measures alongside GAAP results.
- Monitor working-capital and cash conversion, repurchases and dividends, and whether planned hiring and infrastructure spending affect margins.
- Review the full Form 10-K risk factors and contractual-obligation disclosures; this filing says contractual obligations had no material changes but does not reproduce their full schedule.